• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetes

September 15, 2021 By Sean Whooley

Novo Nordisk Foundation Research CenterThe Novo Nordisk Foundation, the Broad Institute of MIT and Harvard have launched an initiative to gain insights into disease mechanisms.

To accelerate efforts to mine genetic data for insights into mechanisms — and eventually rationally design treatments — the trio of entities launched the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease based at the Broad Institute in Cambridge, Massachusetts.

Novo Nordisk’s foundation will support the launch with a grant of up to $47.5 million as the center aims to generate systematic datasets to help researchers understand how human genetic variants affect risk for common complex diseases, with all datasets to be shared freely with the research community, according to a news release.

Initially, the Novo Nordisk Foundation has committed to a five-year period (2021 to 2026) of support with the possibility of extending its support of the research center beyond that.

Copenhagen, Denmark-based Novo Nordisk’s foundation aims to launch and facilitate close collaborations between the Broad Institute and researchers at Danish universities, with the initial focus centered on understanding type 2 diabetes and obesity and mapping human gene regulation. The new research center will establish an exchange program to provide opportunities for Danish scientists to study genomic technologies at the Broad Institute while biomedical research is expanded in Denmark.

“With its leading universities and hospitals, Boston is renowned as an international epicenter for biomedical research and innovation—and the Broad Institute has earned a reputation of being a key nexus in this rich ecosystem,” Novo Nordisk Foundation SVP of biomedicine & health sciences Niels-Henrik von-Holstein-Rathlou said in the release. “By establishing this new center with the Broad Institute, we seek to help drive global research in health for the benefit of many.”

Research will be carried out at the Broad Institute and across Danish institutions, with scientists exchanging dedicated training programs for Danish researchers.

“Starting with our roots in the Human Genome Project, the Broad community has long believed that international collaboration is critical to advancing our knowledge of human disease and getting benefits more quickly to patients,” Broad Institute director Todd Golub said. “The Center for Genomic Mechanisms of Disease is a natural extension of our deep commitment to global collaborations but also our pursuit of foundational research.”

Broad Institute associate member Kasper Lage — also an associate professor of surgery at Harvard Medical School, director of bioinformatics at the Massachusetts General Hospital department of surgery and lead scientist at the Institute for Biological Psychiatry, Mental Health Services, Capital Region of Denmark — will direct the new center.

“As someone who is both a Dane and a long-time member of the Broad Institute community, I am thrilled at the launch of this exciting new Center,” Lage said. “This collaborative initiative will give the next generation of Danish scientists the opportunity to benefit from the Broad’s unique technology platforms as well as our expertise in genomic technologies, gene regulation, and data science. I am grateful for the tremendous vision of the Novo Nordisk Foundation for this new type of collaborative initiative and to everyone there who made this exciting partnership possible.”

Filed Under: Business/Financial News, Diabetes, Featured, Funding Roundup, Research & Development Tagged With: Broad Institute, Harvard University, mit, Novo Nordisk

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS